Ospedale San Donato

Running trials

• Recruiting

  Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting

  NCT07109375· Chiesi Italia· Source

• Recruiting

  TRanscatheter Aortic-Valve Implantation Without On-site Cardiac Surgery

  NCT07604402· University Hospital of Ferrara· Source

• Not yet recruiting

  XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients

  NCT07381777· Phase 2· Gruppo Oncologico Italiano di Ricerca Clinica· Source

• Active, not recruiting

  TRanscatheter Aortic-Valve Implantation With or Without On-site Cardiac Surgery: the TRACS Trial

  NCT05751577· Azienda Usl di Bologna· Source

• Recruiting

  Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

  NCT05817903· Phase 2· Consorzio Oncotech· Source

• Recruiting

  ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing

  NCT06324682· University Hospital of Ferrara· Source

• Recruiting

  Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

  NCT05601700· Phase 3· Ente Ospedaliero Ospedali Galliera· Source

• Recruiting

  Italian Anderson Fabry Disease Cardiovascular Registry

  NCT06806813· IRCCS Azienda Ospedaliero-Universitaria di Bologna· Source

• Active, not recruiting

  Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

  NCT04988386· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Recruiting

  Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease

  NCT04912323· R3 Vascular Inc.· Source

• Recruiting

  A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations

  NCT04811001· Phase 2· Fondazione Ricerca Traslazionale· Source

• Active, not recruiting

  Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

  NCT02811861· Phase 3· Eisai Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fabry disease2 recruiting
• Aortic stenosis1 recruiting
• Atrial fibrillation1 recruiting
• Childhood cancers1 recruiting
• Heart failure1 recruiting
• Kidney cancer1 recruiting
• Ovarian cancer1 recruiting
• Peripheral artery disease1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs

  NCT06316128· Heart Care Foundation· Source

• Terminated

  Blue Light Photobiomodulation Therapy on Neuroischemic Patients

  NCT04831606· Emoled· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· pharmaand GmbH· Source

• Completed

  IN.PACT BTK Randomized Study to Assess Safety and Efficacy of IN.PACT 014 vs. PTA

  NCT02963649· Medtronic Endovascular· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Myocarditis9 works · 0 trials